They must, like why?
but can't rule it out either.
Is that true? Joke?
tough question that ibmwatcher ignores
and? What's your point that you sat there and watched?
CGEN is quite interesting as a spec biotech, no doubt. Even though it has had a double, people like Steve are willing to put another $100K into this. That could provide support at these extended levels, and hence another leg up with good news.